Long-Term Expression and Safety of Administration of AAVrh.10hCLN2 to the Brain of Rats and Nonhuman Primates for the Treatment of Late Infantile Neuronal Ceroid Lipofuscinosis

Adeno-Associated Virus Antibody Profiles in Newborns, Children, and Adolescents

(2011) Roberto Calcedo et al.   Clinical and Vaccine Immunology

Prevalence of Serum IgG and Neutralizing Factors Against Adeno-Associated Virus (AAV) Types 1, 2, 5, 6, 8, and 9 in the Healthy Population: Implications for Gene Therapy Using AAV Vectors

(2010) Sylvie Boutin et al.   HUMAN GENE THERAPY

RH10 provides superior transgene expression in mice when compared with natural AAV serotypes for neonatal gene therapy

(2010) Chuhong Hu et al.   JOURNAL OF GENE MEDICINE

Naturally occurring singleton residues in AAV capsid impact vector performance and illustrate structural constraints

(2009) L H Vandenberghe et al.   GENE THERAPY

Worldwide Epidemiology of Neutralizing Antibodies to Adeno‐Associated Viruses

(2009) Roberto Calcedo et al.   JOURNAL OF INFECTIOUS DISEASES

Survival advantage of neonatal CNS gene transfer for late infantile neuronal ceroid lipofuscinosis

(2008) Dolan Sondhi et al.   EXPERIMENTAL NEUROLOGY

Treatment of Late Infantile Neuronal Ceroid Lipofuscinosis by CNS Administration of a Serotype 2 Adeno-Associated Virus Expressing CLN2 cDNA

(2008) Stefan Worgall et al.   HUMAN GENE THERAPY

Transgene Expression, Bioactivity, and Safety of CERE-120 (AAV2-Neurturin) Following Delivery to the Monkey Striatum

(2008) Christopher D Herzog et al.   MOLECULAR THERAPY